Literature DB >> 18612547

Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells.

Xiaofeng Jiang1, Shimei Zhu, Tracee S Panetti, Michael E Bromberg.   

Abstract

Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with activated factor VII (FVIIa). TF is constitutively expressed in a variety of tumor cells and has been implicated in cellular signaling, angiogenesis, and tumor progression. Formation of TF-FVIIa complex and generation of downstream coagulation proteases, including activated factor X (FXa) and thrombin, initiate signaling by activation of protease-activated receptors (PARs). We have previously shown that TF-FVIIa-Xa complex formation promotes phosphorylation of p44/42 mitogen-activated protein kinase and Akt/protein kinase B in human breast cancer cells. In the present study, we show that formation of TF-FVIIa-FXa complex induces phosphorylation of mammalian target of rapamycin (mTOR) and p70 S6 kinase in a human breast cancer cell line, Adr-MCF-7. Activation of the mTOR pathway, which is probably mediated by PAR1 and/or PAR2, was associated with enhanced cell migration, a key step in the metastatic cascade. Inhibition of this pathway with the specific mTOR inhibitor, rapamycin, markedly decreased cell migration induced by formation of TF-FVIIa-FXa complex. These studies suggest that TF-FVIIa-mediated signaling modulates mTOR pathway activation, which regulates in part breast cancer cell migration. Targeting the TF-mediated cell signaling pathway might represent a novel strategy for the treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612547     DOI: 10.1160/TH07-12-0722

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

1.  F10 gene hypomethylation, a putative biomarker for glioma prognosis.

Authors:  Xiaoping Liu; Hailin Tang; Zeyou Wang; Chen Huang; Zuping Zhang; Xiaoling She; Minghua Wu; Guiyuan Li
Journal:  J Neurooncol       Date:  2011-12-13       Impact factor: 4.130

Review 2.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

3.  Protease-activated receptor 1 and 4 signal inhibition reduces preterm neonatal hemorrhagic brain injury.

Authors:  Tim Lekic; Damon Klebe; Devin W McBride; Anatol Manaenko; William B Rolland; Jerry J Flores; Orhan Altay; Jiping Tang; John H Zhang
Journal:  Stroke       Date:  2015-04-30       Impact factor: 7.914

Review 4.  Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis.

Authors:  Giovanni Cimmino; Plinio Cirillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

5.  Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro.

Authors:  Camille Ettelaie; Donna Fountain; Mary Elizabeth W Collier; Ellie Beeby; Yu Pei Xiao; Anthony Maraveyas
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

6.  Tissue factor-dependent chemokine production aggravates experimental colitis.

Authors:  Karla C S Queiroz; Cornelis Van 't Veer; Yascha Van Den Berg; Janwillem Duitman; Henri H Versteeg; Hella L Aberson; Angelique P Groot; Marleen I Verstege; Joris J T H Roelofs; Anje A Te Velde; C Arnold Spek
Journal:  Mol Med       Date:  2011-06-22       Impact factor: 6.354

Review 7.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Tissue factor as a novel target for treatment of breast cancer.

Authors:  Marion Cole; Michael Bromberg
Journal:  Oncologist       Date:  2013-01-03

Review 9.  Targeting clotting proteins in cancer therapy - progress and challenges.

Authors:  Wolfram Ruf; Andrea S Rothmeier; Claudine Graf
Journal:  Thromb Res       Date:  2016-04       Impact factor: 3.944

10.  Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109.

Authors:  Alexandra Hockla; Derek C Radisky; Evette S Radisky
Journal:  Breast Cancer Res Treat       Date:  2009-12-25       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.